Traditionally, prostate-specific antigen (PSA) is used to identify men at increased risk of prostate cancer, for follow-up of men on active surveillance for low-risk prostate cancer, and for control of men after treatment for prostate cancer. Here, KLK3 is linked to prostate cancer.